An intact HDM2 RING-finger domain is required for nuclear exclusion of p53

被引:0
|
作者
Scott D. Boyd
Kenneth Y. Tsai
Tyler Jacks
机构
[1] MIT Center for Cancer Research,Department of Biology Massachusetts Institute of Technology
[2] Harvard-MIT Division of Health Sciences Technology,undefined
[3] Howard Hughes Medical Institute,undefined
来源
Nature Cell Biology | 2000年 / 2卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The p53 tumour-suppressor protein is negatively regulated by HDM2. Recent reports indicate that the leucine-rich nuclear-export sequence (NES) of HDM2 enables it to shuttle to the cytoplasm, and that this activity is required for degradation of p53. However, it is unclear whether HDM2 is involved in nuclear export of p53, partly because p53 has itself been shown to contain a functional NES within its tetramerization domain. Here we show that co-expression of HDM2 with green fluorescent protein (GFP)-tagged p53 causes redistribution of p53 from the nucleus to the cytoplasm of the cell. This activity is dependent on binding of p53 to HDM2, and requires an intact p53 NES, but is independent of the HDM2 NES. A mutant of the HDM2 RING-finger domain that is unable to ubiquitinate p53 does not cause relocalization of p53, indicating that ubiquitin ligation or other activities of this region of HDM2 may be necessary for its regulation of p53 localization.
引用
收藏
页码:563 / 568
页数:5
相关论文
共 50 条
  • [41] Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination
    Chen, Zhenping
    Knutson, Eugene
    Wang, Shuo
    Martinez, Luis A.
    Albrecht, Thomas
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (40) : 29284 - 29295
  • [42] Deregulation of the p53/HDM2/p14ARF pathway in ductal adenocarcinomas of the pancreas
    Geradts, J
    Roberts, H
    Kern, S
    Hruban, R
    Wilentz, R
    MODERN PATHOLOGY, 2003, 16 (01) : 273A - 273A
  • [43] Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors
    Lai, ZH
    Yang, T
    Kim, YB
    Sielecki, TM
    Diamond, MA
    Strack, P
    Rolfe, M
    Caligiuri, M
    Benfield, PA
    Auger, KR
    Copeland, RA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (23) : 14734 - 14739
  • [44] Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage
    Joseph, TW
    Zaika, A
    Moll, UM
    FASEB JOURNAL, 2003, 17 (12): : 1622 - 1630
  • [45] Deregulation of the p53/HDM2/p14ARF pathway in ductal adenocarcinomas of the pancreas
    Geradts, J
    Roberts, H
    Kern, S
    Hruban, R
    Wilentz, R
    LABORATORY INVESTIGATION, 2003, 83 (01) : 273A - 273A
  • [46] Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic
    Carry, Jean-Christophe
    Garcia-Echeverria, Carlos
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (09) : 2480 - 2485
  • [47] hnRNP K: An HDM2 target and transcriptional coactivator of p53 in response to DNA damage
    Moumen, A
    Masterson, P
    O'Connor, MJ
    Jackson, SP
    CELL, 2005, 123 (06) : 1065 - 1078
  • [48] AURKA-mediated Activation of HDM2 Regulates p53 in Upper Gastrointestinal Cancers
    Sehdev, Vikas
    Katsha, Ahmed M.
    Peng, DunFa
    Belkhiri, Abbes
    Soutto, Mohammed
    Ecsedy, Jeffrey
    Zaika, Alexander
    El-Rifai, Wael
    GASTROENTEROLOGY, 2013, 144 (05) : S167 - S167
  • [49] Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2
    Kitagaki, Jirouta
    Agama, Keli K.
    Pommier, Yves
    Yang, Yili
    Weissman, Allan M.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (08) : 2445 - 2454
  • [50] Activated Akt expression in breast cancer: Correlation with p53, Hdm2 and patient outcome
    Vestey, SB
    Sen, C
    Calder, CJ
    Perks, CM
    Pignatelli, M
    Winters, ZE
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (07) : 1017 - 1025